777 – Time to Stable Sputum Culture Positivity as a Surrogate Endpoint in Phase II/III Tuberculosis Trials
Background Tuberculosis (TB) remains a global health challenge, with an estimated 10.8 million cases reported annually. Although the standard 6-month regimen-comprising isoniazid, rifampicin, pyrazinamide, and ethambutol (HRZE)-is effective in clinical trials, its long duration leads to poor adherence and adverse outcomes in practice. Positive culture at month 2 (PCM2) has traditionally served as a milestone endpoint,…